78.70 +2.50 (3.28%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
76.4
Today’s High
79.75
52 Week Low
75.3
52 Week High
168.2
78.95 +2.75 (3.61%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
76.3
Today’s High
79.8
52 Week Low
75.3
52 Week High
168.55
Key Metrics
- Market Cap (In Cr) 1985.28
- Beta 0.69
- Div. Yield (%) 0
- P/B 2.87
- TTM P/E 366.87
- Peg Ratio -3.16
- Sector P/E 28.26
- D/E 0.58
- Open Price 77.05
- Prev Close 76.2
Analysis
Price Analysis
-
1 Week-7.74%
-
3 Months-19.94%
-
6 Month-37.46%
-
YTD-8.79%
-
1 Year-51.09%
Risk Meter
- 39% Low risk
- 39% Moderate risk
- 39% Balanced Risk
- 39% High risk
- 39% Extreme risk
Recos
0 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Sequent Scientific News
Stocks to Watch: DHFL, Tata Group, Indian Oil Corp, HCC, Sequent Scientific
2 min read . 23 Sep 2020
PE firm Carlyle to acquire up to 74% stake in SeQuent Scientific for ₹1,580 cr
1 min read . 08 May 2020Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 1412.82
- Selling/ General/ Admin Expenses Total
- 231.37
- Depreciation/ Amortization
- 51.54
- Other Operating Expenses Total
- 279.05
- Total Operating Expense
- 1354.96
- Operating Income
- 57.86
- Net Income Before Taxes
- 52.93
- Net Income
- 40.96
- Diluted Normalized EPS
- 1.65
- Period
- 2022
- Total Assets
- 1450.97
- Total Liabilities
- 758.87
- Total Equity
- 692.1
- Tangible Book Valueper Share Common Eq
- 17.81
- Period
- 2022
- Cashfrom Operating Activities
- 32.06
- Cashfrom Investing Activities
- -95.57
- Cashfrom Financing Activities
- 67.26
- Net Changein Cash
- 3.75
- Period
- 2021
- Total Revenue
- 1361.62
- Selling/ General/ Admin Expenses Total
- 370.63
- Depreciation/ Amortization
- 50.6
- Other Operating Expenses Total
- 23.03
- Total Operating Expense
- 1204.75
- Operating Income
- 156.86
- Net Income Before Taxes
- 136.63
- Net Income
- 95.44
- Diluted Normalized EPS
- 4.1
- Period
- 2021
- Total Assets
- 1392.56
- Total Liabilities
- 664.91
- Total Equity
- 727.65
- Tangible Book Valueper Share Common Eq
- 20.5
- Period
- 2021
- Cashfrom Operating Activities
- 114.75
- Cashfrom Investing Activities
- 9.65
- Cashfrom Financing Activities
- -138.75
- Net Changein Cash
- -14.35
- Period
- 2020
- Total Revenue
- 1179.24
- Selling/ General/ Admin Expenses Total
- 331.06
- Depreciation/ Amortization
- 50.62
- Other Operating Expenses Total
- 21.22
- Total Operating Expense
- 1054.06
- Operating Income
- 125.19
- Net Income Before Taxes
- 94.08
- Net Income
- 69.9
- Diluted Normalized EPS
- 2.85
- Period
- 2020
- Total Assets
- 1462.65
- Total Liabilities
- 775.54
- Total Equity
- 687.1
- Tangible Book Valueper Share Common Eq
- 18.24
- Period
- 2020
- Cashfrom Operating Activities
- 115.33
- Cashfrom Investing Activities
- -72.27
- Cashfrom Financing Activities
- -42.75
- Net Changein Cash
- 0.31
- Period
- 2019
- Total Revenue
- 1039.31
- Selling/ General/ Admin Expenses Total
- 298.18
- Depreciation/ Amortization
- 41.92
- Other Operating Expenses Total
- 20.22
- Total Operating Expense
- 948.55
- Operating Income
- 90.75
- Net Income Before Taxes
- 58.88
- Net Income
- 48.66
- Diluted Normalized EPS
- 1.98
- Period
- 2019
- Total Assets
- 1387.88
- Total Liabilities
- 681.19
- Total Equity
- 706.69
- Tangible Book Valueper Share Common Eq
- 17.42
- Period
- 2019
- Cashfrom Operating Activities
- 116.02
- Cashfrom Investing Activities
- -67.7
- Cashfrom Financing Activities
- -20.08
- Net Changein Cash
- 28.24
- Period
- 2018
- Total Revenue
- 849.45
- Selling/ General/ Admin Expenses Total
- 249.56
- Depreciation/ Amortization
- 41.77
- Other Operating Expenses Total
- 13.14
- Total Operating Expense
- 805.19
- Operating Income
- 44.25
- Net Income Before Taxes
- 23.64
- Net Income
- 421.57
- Diluted Normalized EPS
- 0.06
- Period
- 2018
- Total Assets
- 1342.76
- Total Liabilities
- 695.19
- Total Equity
- 647.58
- Tangible Book Valueper Share Common Eq
- 15.61
- Period
- 2018
- Cashfrom Operating Activities
- 45.24
- Cashfrom Investing Activities
- 7.17
- Cashfrom Financing Activities
- -56.96
- Net Changein Cash
- -4.55
- Period
- 2017
- Total Revenue
- 689.01
- Selling/ General/ Admin Expenses Total
- 227.37
- Depreciation/ Amortization
- 41.62
- Other Operating Expenses Total
- 12.61
- Total Operating Expense
- 671.09
- Operating Income
- 17.91
- Net Income Before Taxes
- -14.39
- Net Income
- -13.82
- Diluted Normalized EPS
- -0.46
- Period
- 2017
- Total Assets
- 1904.61
- Total Liabilities
- 927.82
- Total Equity
- 976.79
- Tangible Book Valueper Share Common Eq
- 27.12
- Period
- 2017
- Cashfrom Operating Activities
- -7.19
- Cashfrom Investing Activities
- -116.18
- Cashfrom Financing Activities
- 147.44
- Net Changein Cash
- 24.07
- Period
- 2022-09-30
- Total Revenue
- 337.61
- Selling/ General/ Admin Expenses Total
- 62.46
- Depreciation/ Amortization
- 13.38
- Other Operating Expenses Total
- 71.05
- Total Operating Expense
- 344.78
- Operating Income
- -7.17
- Net Income Before Taxes
- -17.72
- Net Income
- -3.75
- Diluted Normalized EPS
- -0.15
- Period
- 2022-09-30
- Total Assets
- 1493.42
- Total Liabilities
- 755.88
- Total Equity
- 737.54
- Tangible Book Valueper Share Common Eq
- 17.62
- Period
- 2022-09-30
- Cashfrom Operating Activities
- -47.51
- Cashfrom Investing Activities
- -31.72
- Cashfrom Financing Activities
- 60.69
- Net Changein Cash
- -18.54
- Period
- 2022-06-30
- Total Revenue
- 341.32
- Selling/ General/ Admin Expenses Total
- 64.49
- Depreciation/ Amortization
- 13.93
- Other Operating Expenses Total
- 74
- Total Operating Expense
- 352.32
- Operating Income
- -11
- Net Income Before Taxes
- -20.93
- Net Income
- -14.97
- Diluted Normalized EPS
- -0.52
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 383.71
- Selling/ General/ Admin Expenses Total
- 57.18
- Depreciation/ Amortization
- 12.93
- Other Operating Expenses Total
- 74.38
- Total Operating Expense
- 363.29
- Operating Income
- 20.42
- Net Income Before Taxes
- 18.15
- Net Income
- 8.67
- Diluted Normalized EPS
- 0.34
- Period
- 2022-03-31
- Total Assets
- 1450.97
- Total Liabilities
- 758.87
- Total Equity
- 692.1
- Tangible Book Valueper Share Common Eq
- 17.81
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 32.06
- Cashfrom Investing Activities
- -95.57
- Cashfrom Financing Activities
- 67.26
- Net Changein Cash
- 3.75
- Period
- 2021-12-31
- Total Revenue
- 358.05
- Selling/ General/ Admin Expenses Total
- 46.28
- Depreciation/ Amortization
- 12.83
- Other Operating Expenses Total
- 68.03
- Total Operating Expense
- 334.66
- Operating Income
- 23.39
- Net Income Before Taxes
- 23.6
- Net Income
- 17.12
- Diluted Normalized EPS
- 0.69
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 350.55
- Selling/ General/ Admin Expenses Total
- 62.26
- Depreciation/ Amortization
- 13.21
- Other Operating Expenses Total
- 68.2
- Total Operating Expense
- 344.08
- Operating Income
- 6.47
- Net Income Before Taxes
- 3.95
- Net Income
- 14.3
- Diluted Normalized EPS
- 0.57
- Period
- 2021-09-30
- Total Assets
- 1439.88
- Total Liabilities
- 679.05
- Total Equity
- 760.84
- Tangible Book Valueper Share Common Eq
- 21.91
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 11.29
- Cashfrom Investing Activities
- -11.93
- Cashfrom Financing Activities
- 8.61
- Net Changein Cash
- 7.97
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day83.51
- 10 Day85.22
- 20 Day85.99
- 50 Day88.87
- 100 Day96.79
- 300 Day106.71
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Shilpa Medicare
- 246.25
- 5.15
- 2.14
- 538.5
- 239.85
- 2094.96
- Amrutanjan Health Care
- 718.95
- 3.8
- 0.53
- 955
- 685.25
- 2079.49
- Sequent Scientific
- 78.7
- 2.5
- 3.28
- 168.2
- 75.3
- 1985.28
- Alembic
- 68.9
- 1.7
- 2.53
- 102.85
- 56.5
- 1761.52
- Supriya Lifescience
- 213.85
- 5.2
- 2.49
- 515.35
- 207.8
- 1715.89
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Shilpa Medicare
- 35.74
- 1.15
- 8.96
- 12.81
- Amrutanjan Health Care
- 31.01
- 7.86
- 23.64
- 13.46
- Sequent Scientific
- 48.42
- 2.87
- 7.1
- 5.11
- Alembic
- 8.01
- 0.71
- 16.47
- 58.12
- Supriya Lifescience
- 11.32
- 2.79
- -
- -
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 46.82%
- 116,791,142
- Others
- 25.1%
- 62,611,718
- UNIT TRUST OF INDIA INVESTMENT ADVISORY SERVICES L
- 3.33%
- 8,309,763
- Others
- 3.51%
- 8,769,247
- ASHOKA INDIA OPPORTUNITIES FUND
- 1.64%
- 4,078,604
- Others
- 4.61%
- 11,511,419
- Others
- 3.5%
- 8,739,812
- Others
- 1.35%
- 3,368,115
- Others
- 1.24%
- 3,094,703
- ICICI LOMBARD GENERAL INSURANCE COMPANY LTD
- 1.21%
- 3,014,026
- HUF
- 1%
- 2,490,989
- Clearing Members
- 0.04%
- 109,967
- Trusts
- 0.02%
- 45,203
- Others
- 0.25%
- 621,408
- Others
- 0.01%
- 22,900
- Others
- 0%
- 3,268
- Non Promoter - Non Public shareholder
- 0.39%
- 962,250
- Others
- 0.39%
- 962,250
- Promoter & Promoter Group Shareholding
- 52.79%
- 131,680,103
- CA HARBOR INVESTMENTS
- 52.79%
- 131,680,103
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 07-Nov-22
- Quarterly Results & Preferential issue
- 08-Aug-22
- Quarterly Results
- 25-May-22
- Audited Results
- 11-Feb-22
- Quarterly Results
- 01-Nov-21
- Quarterly Results
- 10-Aug-21
- Quarterly Results
- 30-Jun-21
- Audited Results & Final Dividend
- 03-Feb-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 11-Apr-22
- 11-Mar-22
- POM
- 16-Mar-21
- 12-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 01-Jul-21
- 10-Sept-21
- 08-Sept-21
- 0.5
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Sequent Scientific
- Industry Biotechnology & Drugs
- ISIN INE807F01027
- BSE Code 512529
- NSE Code SEQUENT
SeQuent Scientific Limited is an India-based integrated pharmaceutical company. The Company operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The Company through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.
MANAGEMENT
- Rajaram Narayanan Chief Executive Officer, Managing Director, Executive Director
- Patri Venkat Raghavendra Rao Chief Financial Officer
- Krunal Shah Compliance Officer, Company Secretary
- Prasad Lad Vice President-Human Resources & Admin
- Sharat Narasapur Joint Managing Director, Executive Director
- Yawar Abbas Emerging markets
- Jose Filho Latin America Operations
- Alexis Goux Global Formulations
- Murat Goux Global Formulations
- Ashish Kakabalia Business Development and R&D
Company Summary
SEQUENT SCIENTIFIC SUMMARY
Sequent Scientific is trading 3.28% upper at Rs 78.70 as compared to its last closing price. Sequent Scientific has been trading in the price range of 79.75 & 76.4. Sequent Scientific has given -8.79% in this year & -7.74% in the last 5 days.
Sequent Scientific has TTM P/E ratio 366.87 as compared to the sector P/E of 28.26.
The company posted a net profit of -3.75 Crores in its last quarter.
Listed peers of Sequent Scientific include Shilpa Medicare (2.14%), Amrutanjan Health Care (0.53%), Sequent Scientific (3.28%) etc.
Sequent Scientific has a 52.79% promoter holding & 0.39% public holding.
FAQs about Sequent Scientific
Sequent Scientific is trading at 78.70 as on 31 Jan, 2023 1:06:13 PM. This is 3.28% upper as compared to its previous closing price of 76.2
The market capitalization of Sequent Scientific is 1985.28 Cr as on 31 Jan, 2023 1:06:13 PM.
The 52 wk high for Sequent Scientific is 168.2 whereas the 52 wk low is 75.3
Sequent Scientific can be analyzed on the following key metrics -
- TTM P/E: 366.87
- Sector P/E: 28.26
- Dividend Yield: 0%
- D/E ratio: -
Sequent Scientific reported a net profit of 40.96 Cr in 2022.
